{"id":70719,"date":"2026-05-12T09:49:37","date_gmt":"2026-05-12T09:49:37","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70719"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"follistatin-344","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/follistatin-344\/","title":{"rendered":"Follistatine 344"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que la Follistatine 344 ?<\/h3>\n<p style=\"margin: 0;\"><strong>Follistatine 344<\/strong> (FST-344) is a 344-amino-acid recombinant glycoprotein and the longer of the two principal splice isoforms of human follistatin. It is the canonical endogenous antagonist of myostatin (GDF-8) and activin, used in published studies investigating muscle hypertrophy, sarcopenia, muscular dystrophy preclinical models, and the activin\/myostatin signalling axis. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">80449-31-6 (follistatine)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Type<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Glycoprot\u00e9ine recombinante (isoforme d'\u00e9pissage FST-344 de 344 acides amin\u00e9s de la follistatine humaine)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~37 kDa (forme glycosyl\u00e9e mature ; plage observ\u00e9e de ~38\u201342 kDa sur SDS-PAGE selon l'\u00e9tat de glycosylation)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Structure<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Domaine de liaison \u00e0 l'h\u00e9parine en N-terminal suivi de trois domaines de follistatine (FSD1, FSD2, FSD3) contenant chacun un sous-domaine de type EGF et un sous-domaine de type Kazal ; riche en cyst\u00e9ine, multiples liaisons disulfure intramol\u00e9culaires<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prot\u00e9ine recombinante lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595% (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, utiliser dans les ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e \u2014 les prot\u00e9ines recombinantes sont particuli\u00e8rement sensibles \u00e0 la d\u00e9naturation par cong\u00e9lation-d\u00e9cong\u00e9lation.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes. Prot\u00e9ine porteuse (BSA, 0,1%) optionnelle pour les dilutions de travail afin de minimiser les pertes par adsorption.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que la Follistatine 344 ?<\/h2>\n<p><strong>Follistatine 344<\/strong> (often abbreviated FST-344) is a recombinant 344-amino-acid glycoprotein and the longer of the two principal physiological splice isoforms of human follistatin \u2014 the other being FST-288, a shorter 288-amino-acid membrane-bound form. Endogenous follistatin was first isolated in 1987 from porcine ovarian follicular fluid by Esch et al. (PNAS) and Robertson et al. (Biochem Biophys Res Commun) as a factor that selectively inhibits follicle-stimulating hormone (FSH) secretion, which gave the protein its name. The mechanistic role \u2014 high-affinity binding and neutralisation of activin and myostatin \u2014 was characterised over the subsequent decade. FST-344 is a circulating, secreted isoform with a heparin-binding N-terminal domain followed by three cysteine-rich follistatin domains (FSD1, FSD2, FSD3) that together form the activin- and myostatin-binding surface. The recombinant 344-residue chain has a mature mass of approximately 37\u00a0kDa, with apparent molecular weight on SDS-PAGE varying between 38 and 42\u00a0kDa depending on the glycosylation state of the recombinant expression system. CAS number 80449-31-6. The protein is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Follistatin is <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related anabolic and growth-axis studies, see our <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> page produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Antagonisme de la voie de la myostatine et de l'activine<\/h2>\n<p>What makes follistatin 344 mechanistically unique among muscle-studies proteins is its <strong>profil de liaison multi-cibles<\/strong> across the TGF-\u03b2 superfamily \u2014 each ligand-binding event contributing to the observed hypertrophic and growth-modulatory phenotype in published studies:<\/p>\n<ul>\n<li><strong>S\u00e9questration de la myostatine (GDF-8) \u2014 axe d'hypertrophie musculaire<\/strong> \u2014 Follistatin binds myostatin (also called GDF-8) with high affinity, sterically blocking its interaction with the activin type II receptor (ActRIIB). Myostatin is the canonical endogenous negative regulator of muscle growth: knockout mice develop dramatic muscle hypertrophy (the &#8220;double-muscling&#8221; phenotype), and naturally myostatin-deficient cattle breeds (Belgian Blue, Piedmontese) show the same effect. By neutralising myostatin, follistatin removes the brake on muscle protein synthesis, producing hypertrophy in study models. This is the most-cited mechanism in the muscle-literature.<\/li>\n<li><strong>S\u00e9questration de l'activine A et B \u2014 signalisation reproductive, ovarienne et hypophysaire<\/strong> \u2014 Follistatin&#8217;s original characterised function was binding and neutralising activin, a related TGF-\u03b2 superfamily member that stimulates FSH secretion from the pituitary, drives ovarian follicle development, and acts as a regulator of many cell types. By binding activin A, B, and AB heterodimers, follistatin shifts the activin\/inhibin balance in study models and modulates downstream Smad2\/Smad3 signalling.<\/li>\n<li><strong>Modulation de GDF-11 et de la superfamille \u00e9largie des TGF-\u03b2<\/strong> \u2014 Follistatin also binds GDF-11 (closely related to myostatin) with somewhat lower affinity, alongside other TGF-\u03b2 superfamily members. GDF-11 is increasingly studied in aging studies because its endogenous levels decline with age and its modulation is implicated in age-related cardiac and CNS phenotypes. Follistatin 344 is one of the principal tools for investigating this axis.<\/li>\n<\/ul>\n<p>The three follistatin domains (FSD1, FSD2, FSD3) each contribute to the binding profile: FSD1 contains the principal myostatin-binding surface, FSD2 the principal activin-binding surface, and FSD3 contributes both binding affinity and structural stability. The heparin-binding N-terminal domain distinguishes the splice variants \u2014 FST-288 binds heparan sulfate strongly and is largely membrane-anchored, while FST-344 (this isoform) circulates more freely. This distinction is mechanistically relevant in study models studying systemic vs local follistatin effects. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Follistatin 344 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle hypertrophy and protein synthesis studies<\/strong> \u2014 mod\u00e8les d'hypertrophie chez la souris et le rat, y compris les \u00e9tudes de d\u00e9livrance g\u00e9nique par AAV-follistatine (Kota et al., Sci Transl Med 2009) ; aire de section transversale sp\u00e9cifique au type de fibre, poids humide du muscle, g\u00e9n\u00e9ration de force<\/li>\n<li><strong>Mod\u00e8les pr\u00e9cliniques de dystrophie musculaire<\/strong> \u2014 mod\u00e8le murin mdx de dystrophie musculaire de Duchenne ; capacit\u00e9 fonctionnelle, r\u00e9g\u00e9n\u00e9ration des fibres, pr\u00e9servation musculaire ind\u00e9pendante de la dystrophine<\/li>\n<li><strong>Sarcop\u00e9nie et perte musculaire li\u00e9e \u00e0 l'\u00e2ge<\/strong> \u2014 aged-mouse muscle phenotypes, anabolic resistance, fibre-type-shift studies<\/li>\n<li><strong>Cancer cachexia studies<\/strong> \u2014 mod\u00e8les de cachexie chez les souris porteuses de tumeurs, pr\u00e9servation de la composition corporelle, rapport masse maigre \/ masse grasse<\/li>\n<li><strong>Reproductive endocrinology studies<\/strong> \u2014 FSH suppression, ovarian follicle development, granulosa-cell biology, pituitary-gonadal-axis studies<\/li>\n<li><strong>Activin pathway studies<\/strong> \u2014 Smad2\/Smad3 signalling, EMT in cancer models, fibrosis studies, hepatic regeneration<\/li>\n<li><strong>Aging and GDF-11 axis studies<\/strong> \u2014 cardiac and CNS aging phenotypes, parabiosis-related studies, GDF-11\/myostatin balance with aging<\/li>\n<li><strong>Comparative anabolic studies<\/strong> \u2014 comparaison directe avec <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> (parallel anabolic pathway via IGF-1 receptor) for combined or comparative hypertrophy studies.<\/li>\n<\/ul>\n<p>For broader context on where follistatin 344 fits within the anabolic and growth-axis studies landscape, see <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> comme comparateur canonique de l'axe IGF, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for GHRH-axis growth studies, and <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 muscle hypertrophy and activin\/myostatin axis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Follistatin 344 is a 37\u00a0kDa recombinant glycoprotein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format is the standard strength for in vivo and in vitro work \u2014 one vial reconstituted with 1.0\u00a0mL bacteriostatic water yields a 1\u00a0mg\/mL working concentration sufficient for many weeks of cell-culture protocols or several rodent-protocol injections. <\/p>\n<h2>Comparaison \u2014 Follistatine 344 vs IGF-1 LR3<\/h2>\n<p>Follistatin 344 et <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> are the two most-cited recombinant anabolic proteins in current hypertrophy studies. They act on entirely different pathways \u2014 follistatin by removing the myostatin brake on muscle growth, IGF-1 LR3 by directly stimulating the IGF-1 receptor and downstream Akt\/mTOR protein synthesis \u2014 which makes them mechanistically complementary in protocols. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatine 344<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">IGF-1 LR3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344 acides amin\u00e9s (glycoprot\u00e9ine recombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">83 acides amin\u00e9s (IGF-1 modifi\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~37 kDa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~9 kDa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>M\u00e9canisme principal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00e9questration de la myostatine\/activine<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonisme du r\u00e9cepteur IGF-1 \u2192 Akt\/mTOR<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mode d'action<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D\u00e9sinhibition (l\u00e8ve le frein de croissance)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stimulation anabolique directe<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 mcg, 1\u20133 fois par semaine<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">20\u201360 mcg, quotidiennement<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hypertrophie musculaire globale, mod\u00e8les de dystrophie<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Local hypertrophy, regenerative anabolic studies<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Empilement<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with IGF-1 LR3 in hypertrophy studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Souvent co-administr\u00e9 avec la follistatine 344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Because the two proteins act on fundamentally different anabolic axes \u2014 follistatin removes the myostatin brake while IGF-1 LR3 directly stimulates protein synthesis \u2014 combined administration is commonly used in study models exploring maximal hypertrophic response. For studies interested in the myostatin pathway specifically, follistatin 344 is the canonical first choice; for IGF\/Akt\/mTOR anabolic studies, IGF-1 LR3 is the canonical tool. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> Conservez les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C dans leur emballage d'origine pour un stock de travail \u00e0 court terme. Pour un stockage \u00e0 long terme non ouvert, congelez \u00e0 \u221220 \u00b0C. La follistatine 344 lyophilis\u00e9e est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 12 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 24 mois \u2014 une dur\u00e9e l\u00e9g\u00e8rement plus courte que celle des petits peptides synth\u00e9tiques car la glycoprot\u00e9ine recombinante plus grande est plus sensible \u00e0 la d\u00e9samidation et \u00e0 l'oxydation avec le temps. \u00c9vitez les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation sur la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> injectez de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon de peptide (pas directement sur la poudre lyophilis\u00e9e). Pour un flacon de 1 mg, 1,0 mL d'eau bact\u00e9riostatique donne une concentration de travail de 1 mg\/mL. Tournez doucement \u2014 ne <strong>re\u00e7oit pas<\/strong> Conservez au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C et utilisez dans les 30 jours pour une stabilit\u00e9 optimale. Ne congelez pas la solution reconstitu\u00e9e \u2014 les glycoprot\u00e9ines recombinantes sont particuli\u00e8rement sensibles \u00e0 la d\u00e9naturation par cong\u00e9lation-d\u00e9cong\u00e9lation, ce qui entra\u00eene une agr\u00e9gation et une perte d'activit\u00e9. Jetez tout flacon pr\u00e9sentant une turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <strong>Apr\u00e8s reconstitution :<\/strong> Conserver au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C et utiliser dans les 30 jours pour une stabilit\u00e9 optimale. Ne pas congeler la solution reconstitu\u00e9e \u2014 les glycoprot\u00e9ines recombinantes sont particuli\u00e8rement sensibles \u00e0 la d\u00e9naturation par cong\u00e9lation-d\u00e9cong\u00e9lation, ce qui entra\u00eene une agr\u00e9gation et une perte d'activit\u00e9. Jeter tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is Follistatin 344 used for in studies?<\/h3>\n<p>Follistatin 344 is used in studies investigating muscle hypertrophy, muscular dystrophy preclinical models, sarcopenia, cancer cachexia, the activin\/myostatin\/GDF-11 signalling axis, reproductive endocrinology (FSH suppression, ovarian follicle development), and aging-related phenotypes. It is the canonical tool for myostatin pathway antagonism. The pharmaceutical-grade follistatin 344 sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Quelle est la diff\u00e9rence entre la Follistatine 344 et la Follistatine 315 ?<\/h3>\n<p>FST-344 est l'isoforme du produit g\u00e9nique de 344 acides amin\u00e9s incluant le peptide signal ; FST-315 est la m\u00eame prot\u00e9ine apr\u00e8s clivage du peptide signal lors de la s\u00e9cr\u00e9tion (donc FST-315 est la forme mature circulante de FST-344). Les deux syst\u00e8mes de nomenclature apparaissent dans la litt\u00e9rature et se r\u00e9f\u00e8rent \u00e0 la m\u00eame isoforme biologique. Les deux diff\u00e8rent consid\u00e9rablement de FST-288, qui est une isoforme plus courte issue d'un \u00e9pissage alternatif, avec une liaison plus forte \u00e0 l'h\u00e9parane sulfate et une localisation principalement membranaire. <\/p>\n<h3>En quoi la Follistatine 344 diff\u00e8re-t-elle de l'IGF-1 LR3 ?<\/h3>\n<p>Both are recombinant anabolic proteins used in muscle hypertrophy studies, but they target different pathways. Follistatin 344 is a 344-amino-acid glycoprotein that binds and sequesters myostatin and activin \u2014 it works by removing the endogenous brake on muscle growth. IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog that directly agonises the IGF-1 receptor and activates Akt\/mTOR protein synthesis. The two are mechanistically complementary and frequently co-administered in studies. <\/p>\n<h3>What is the typical Follistatin 344 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013100\u00a0mcg per administration in rodent models, given 1\u20133 times weekly for 4\u201312 week cycles. Gene-delivery studies using AAV-follistatin produces tissue-localised concentrations that are difficult to compare directly to systemic-protein dosing. A 1\u00a0mg vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 1\u00a0mg\/mL \u2014 0.01\u00a0mL equals 10\u00a0mcg, 0.1\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>La Follistatine 344 est-elle approuv\u00e9e par la FDA ?<\/h3>\n<p>No. Follistatin 344 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. AAV-follistatin gene therapy has been investigated in clinical trials for muscular dystrophy (e.g., Becker muscular dystrophy, inclusion body myositis) but is not FDA-approved. <\/p>\n<h3>Comment la Follistatine 344 doit-elle \u00eatre stock\u00e9e ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour le stock de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les glycoprot\u00e9ines recombinantes sont particuli\u00e8rement sensibles \u00e0 la d\u00e9naturation par cong\u00e9lation-d\u00e9cong\u00e9lation. Prot\u00e9ger de la lumi\u00e8re directe en permanence. Une prot\u00e9ine porteuse (BSA \u00e0 0,1 %) est recommand\u00e9e pour les dilutions de travail inf\u00e9rieures \u00e0 100 mcg\/mL. <\/p>\n<h3>Comment reconstituer la Follistatine 344 ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 5 \u00e0 10 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> agitez le flacon \u2014 une agitation vigoureuse peut d\u00e9naturer les prot\u00e9ines recombinantes et provoquer une agr\u00e9gation. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 1\u00a0mg + 1,0\u00a0mL de diluant, la concentration de travail est de 1\u00a0mg\/mL. <\/p>\n<h3>Pourquoi la sp\u00e9cification de puret\u00e9 est-elle de 95 % plut\u00f4t que de 99 % ?<\/h3>\n<p>Recombinant glycoproteins like follistatin 344 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of the inherent heterogeneity of glycosylation in any recombinant expression system \u2014 different glycoforms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for follistatin 344 and similar recombinant glycoproteins. SDS-PAGE typically shows a single band with the expected 38\u201342\u00a0kDa apparent mass range. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can Follistatin 344 and IGF-1 LR3 be stacked in studies?<\/h3>\n<p>Yes. Follistatin 344 and IGF-1 LR3 act on fundamentally different anabolic axes (myostatin antagonism vs IGF-1 receptor agonism) and are frequently co-administered in study models exploring maximal hypertrophic response. The two are mechanistically complementary rather than redundant, and combined-protocol literature describes additive or synergistic effects on muscle fibre cross-sectional area. <\/p>\n<h3>Does Follistatin 344 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented tolerability at typical doses, with the main on-target effect being muscle hypertrophy. Off-target findings include modulation of FSH and ovarian function (because activin signalling is suppressed) and potential effects on hepatic regeneration and pituitary regulation due to follistatin&#8217;s role in broader TGF-\u03b2 superfamily signalling. Systemic follistatin-protein dosing has different exposure characteristics than tissue-localised AAV-gene-delivery approaches. <\/p>\n<h3>Quelle est la demi-vie de la Follistatine 344 ?<\/h3>\n<p>In preclinical studies, recombinant follistatin 344 has a plasma half-life of approximately 1\u20133 hours following intravenous administration, reflecting its size (37\u00a0kDa, above the renal filtration cutoff) and binding to circulating ligands. Tissue half-life is considerably longer because follistatin remains bound to its captured myostatin and activin targets, sequestering them away from receptors. Gene-delivery approaches produce a far longer effective duration of action because tissue expression continues over weeks to months. <\/p>\n<h3>How long does Follistatin 344 take to show effects in preclinical studies?<\/h3>\n<p>Les effets d'hypertrophie musculaire dans les protocoles d'injection prot\u00e9ique chez la souris et le rat deviennent g\u00e9n\u00e9ralement significatifs statistiquement apr\u00e8s 2 \u00e0 4 semaines d'administration hebdomadaire et continuent de s'accumuler jusqu'\u00e0 8-12 semaines. Les effets sur l'axe activine\/FSH (param\u00e8tres reproductifs) peuvent \u00eatre d\u00e9tect\u00e9s quelques jours apr\u00e8s l'administration. Les protocoles par administration g\u00e9nique (AAV-follistatine) montrent une hypertrophie musculaire mesurable 4 \u00e0 6 semaines apr\u00e8s l'injection, avec des effets qui se d\u00e9veloppent sur plusieurs mois. <\/p>\n<h3>Puis-je commander de la Follistatine 344 pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die la Follistatine 344 dans le monde entier via notre r\u00e9seau d\u00e9di\u00e9 aux peptides. Les commandes contenant uniquement des peptides b\u00e9n\u00e9ficient de notre service d'exp\u00e9dition d\u00e9di\u00e9. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Growth-Axis, and Muscle Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-arginine recombinant IGF-1 analog \u2014 direct IGF-1R agonist for Akt\/mTOR studies<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/fr\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/fr\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Agoniste s\u00e9lectif de la ghr\u00e9line \u2014 pic d'hormone de croissance propre sans cortisol\/prolactine<\/li>\n<li><a href=\"\/fr\/tb-500\/\"><strong>TB-500 (Thymosine B\u00eata-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore anabolic and growth-axis peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s incluant <a href=\"https:\/\/medsbase.com\/fr\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Glycoprot\u00e9ine recombinante 344-aa<br \/>\n\u2705 Antagoniste de la voie myostatine\/activine<br \/>\n\u2705 Muscle hypertrophy compound<br \/>\n\u2705 Mod\u00e8les pr\u00e9cliniques de dystrophie musculaire<br \/>\n\u2705 Puret\u00e9 \u226595% en HPLC, COA sur demande<\/p>\n<p><strong>Follistatine 344<\/strong> est une prot\u00e9ine recombinante.<\/p>","protected":false},"featured_media":70949,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6276,5441],"class_list":["post-70719","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-follistatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70949"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70719"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70719"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70719"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}